- Suppliers
Biogrund 
Evonik 
Capsugel Lonza 
Roquette 
ADM 
Antares 
Armor Pharma 
Asahi KASEI 
Ashland 
BASF 
Beneo 
Captisol 
CarboHyde 
Clariant 
Croda 
DFE Pharma 
Dow 
Excipio Chemicals 
Fuji Chemical 
Gangwal 
Gattefossé 
Grace 
Indovinya 
Ingredient Pharm 
IOI Oleo 
JRS Pharma 
KLK Oleo 
Lactalis 
Lipoid 
Lubrizol Life Science Health 
MAGNESIA 
MEGGLE 
Mingtai Chemical 
Nagase Viita 
Nomisma 
Nordic Bioproducts 
PMC Isochem 
PQ 
Seppic 
ShinEtsu 
Sigachi 
SPI Pharma 
Vikram Thermo 
All4Nutra
- Suppliers
Biogrund Evonik Capsugel Lonza Roquette ADM Antares Armor Pharma Asahi KASEI Ashland BASF Beneo Captisol CarboHyde Clariant Croda DFE Pharma Dow Excipio Chemicals Fuji Chemical Gangwal Gattefossé Grace Indovinya Ingredient Pharm IOI Oleo JRS Pharma KLK Oleo Lactalis Lipoid Lubrizol Life Science Health MAGNESIA MEGGLE Mingtai Chemical Nagase Viita Nomisma Nordic Bioproducts PMC Isochem PQ Seppic ShinEtsu Sigachi SPI Pharma Vikram Thermo - All4Nutra
Development and in-vitro in-vivo characterization of in-situ gelling sustained-release nevirapine suspension
Development and in-vitro in-vivo characterization of in-situ gelling sustained-release nevirapine suspension
Nevirapine is a BCS class-II drug used in the treatment and prevention of HIV/AIDS, specifically HIV-1. This study was aimed to develop and evaluate a novel pH-responsive in-situ gelling sustained-release nevirapine pediatric suspension (SRNPS) for treatment and prevention of mother-to-child transmission of HIV. SRNPS can reduce the number of doses administered with subsequent improvement of patient compliance. Nevirapine anhydrous (NA) is unstable in the suspension formulation which leads to the formation of clusters. So here, initially, nevirapine hemihydrate (NH) was synthesized using NA.
Both NA and NH forms were later evaluated for differential scanning calorimetry (DSC), Fourier transforms infrared spectroscopy (FTIR) and Powder X-Ray diffraction (pXRD). Furthermore, for the preparation of SRNPS NH form was selected. The developed novel SRNPS was compared with marketed immediate-release nevirapine suspension (Viramune®). Further, both suspensions were evaluated for in-vitro drug release studies and in-vivo pharmacokinetic studies using a rat model. SRNPS has shown good in-situ gelling behavior and results have shown sustained drug release for 8 h.
The pharmacokinetic studies in rats also demonstrate an increase in the Cmax, Tmax and AUC for SRNPS compared to Viramune®. The observed Cmax for Viramune® and SRNPS is 0.548 ± 0.16 ng/mL and 0.670 ± 0.22 ng/mL respectively, observed Tmax is 3 ± 0.2 h and 6 ± 0.5 h respectively, while, AUC0-∞ for Viramune® and SRNPS is 26.61 ± 4.26 μg/ml*h and 59.23 ± 5.87 μg/ml*h respectively. The study thus supports the claim that development of SRNPS would minimize the dosing frequency along with sustained action.
Article information: Atul Garkal, Amelia Avachat, Development and in-vitro in-vivo characterization of in-situ gelling sustained-release nevirapine suspension, Journal of Drug Delivery Science and Technology, 2021. https://doi.org/10.1016/j.jddst.2021.102938.
